For context, bariatric surgery typically produces 25 to 30 percent total body weight loss
November 8, 2023
As a dual GLP-1 and GIP receptor agonist, tirzepatide activates two incretin pathways simultaneously
Key benefits Why people compare it 1 22.5% mean body weight reduction at 15mg in SURMOUNT-1 (N=2,539, 72 weeks) 2 Dual GIP/GLP-1 receptor activation for combined metabolic effects beyond single-agonist therapy 3 63% of participants at highest dose achieved at least 20% weight loss vs 1.3% placebo 4 Superior A1C reduction of 2.07-2.59% with up to 97% of diabetic participants reaching target 5 Outperformed semaglutide 1mg head-to-head in SURPASS-2 for both weight and glycemic endpoints 6 Enhanced adipose tissue lipid handling and fat redistribution via GIPR signaling 7 Significant improvements in triglycerides, blood pressure, and waist circumference across all doses 8 Once-weekly dosing supported by 120-hour half-life and C20 fatty diacid albumin binding Deep research Tirzepatide is a 39-amino-acid synthetic peptide with a molecular weight of 4,813.45 Da
Canadian 24-hour movement guidelines for adults aged 18-64 years and adults aged 65 years or older: an integration of physical activity, sedentary behaviour, and sleep
Patients experiencing persistent gastrointestinal adverse effects may benefit from slower titration schedules or maintaining lower doses for longer periods before attempting escalation
